BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li F, Zhao C, Wang L. Molecular-targeted agents combination therapy for cancer: developments and potentials. Int J Cancer 2014;134:1257-69. [PMID: 23649791 DOI: 10.1002/ijc.28261] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Salimian Rizi B, Achreja A, Nagrath D. Nitric Oxide: The Forgotten Child of Tumor Metabolism. Trends Cancer 2017;3:659-72. [PMID: 28867169 DOI: 10.1016/j.trecan.2017.07.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 8.2] [Reference Citation Analysis]
2 Mahe M, Dufour F, Neyret-Kahn H, Moreno-Vega A, Beraud C, Shi M, Hamaidi I, Sanchez-Quiles V, Krucker C, Dorland-Galliot M, Chapeaublanc E, Nicolle R, Lang H, Pouponnot C, Massfelder T, Radvanyi F, Bernard-Pierrot I. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Mol Med 2018;10:e8163. [PMID: 29463565 DOI: 10.15252/emmm.201708163] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
3 Marostica LL, de Barros ALB, Oliveira J, Salgado BS, Cassali GD, Leite EA, Cardoso VN, Lang KL, Caro MSB, Durán FJ, Schenkel EP, de Oliveira MC, Simões CMO. Antitumor effectiveness of a combined therapy with a new cucurbitacin B derivative and paclitaxel on a human lung cancer xenograft model. Toxicology and Applied Pharmacology 2017;329:272-81. [DOI: 10.1016/j.taap.2017.06.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
4 Pandya PH, Murray ME, Pollok KE, Renbarger JL. The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches. J Immunol Res 2016;2016:4273943. [PMID: 28116316 DOI: 10.1155/2016/4273943] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 12.3] [Reference Citation Analysis]
5 Pellosi DS, Paula LB, de Melo MT, Tedesco AC. Targeted and Synergic Glioblastoma Treatment: Multifunctional Nanoparticles Delivering Verteporfin as Adjuvant Therapy for Temozolomide Chemotherapy. Mol Pharm 2019;16:1009-24. [PMID: 30698450 DOI: 10.1021/acs.molpharmaceut.8b01001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
6 Zhang J, Song Q, Liu J, Lu L, Xu Y, Zheng W. Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma. Dis Markers 2019;2019:8964015. [PMID: 31781310 DOI: 10.1155/2019/8964015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Dong J, Aulestia FJ, Assad Kahn S, Zeniou M, Dubois LG, El-Habr EA, Daubeuf F, Tounsi N, Cheshier SH, Frossard N, Junier MP, Chneiweiss H, Néant I, Moreau M, Leclerc C, Haiech J, Kilhoffer MC. Bisacodyl and its cytotoxic activity on human glioblastoma stem-like cells. Implication of inositol 1,4,5-triphosphate receptor dependent calcium signaling. Biochim Biophys Acta Mol Cell Res 2017;1864:1018-27. [PMID: 28109792 DOI: 10.1016/j.bbamcr.2017.01.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
8 Gomez Rodriguez Y, Oliva Arguelles B, Riera-romo M, Fernandez-de-cossio J, Garay HE, Fernandez Masso J, Guerra Vallespi M. Synergic effect of anticancer peptide CIGB-552 and Cisplatin in lung cancer models. Mol Biol Rep. [DOI: 10.1007/s11033-022-07152-3] [Reference Citation Analysis]
9 Woo S, Kim AJ, Choi YK, Shin YC, Cho S, Ko S. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer: A Synergistic Effect of SH003 and Doxorubicin in TNBC Treatment. Phytother Res 2016;30:1817-23. [DOI: 10.1002/ptr.5687] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
10 Zhang M, Mathews Griner LA, Ju W, Duveau DY, Guha R, Petrus MN, Wen B, Maeda M, Shinn P, Ferrer M, Conlon KD, Bamford RN, O'Shea JJ, Thomas CJ, Waldmann TA. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. Proc Natl Acad Sci U S A 2015;112:12480-5. [PMID: 26396258 DOI: 10.1073/pnas.1516208112] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 7.3] [Reference Citation Analysis]
11 Stevens AM, Xiang M, Heppler LN, Tošić I, Jiang K, Munoz JO, Gaikwad AS, Horton TM, Long X, Narayanan P, Seashore EL, Terrell MC, Rashid R, Krueger MJ, Mangubat-Medina AE, Ball ZT, Sumazin P, Walker SR, Hamada Y, Oyadomari S, Redell MS, Frank DA. Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood Adv 2019;3:4215-27. [PMID: 31856268 DOI: 10.1182/bloodadvances.2019000499] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
12 Valli D, Gruszka AM, Alcalay M. Has Drug Repurposing Fulfilled its Promise in Acute Myeloid Leukaemia? J Clin Med 2020;9:E1892. [PMID: 32560371 DOI: 10.3390/jcm9061892] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
13 Choucair K, Kamran S, Saeed A. Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy. Onco Targets Ther 2021;14:5521-32. [PMID: 35002257 DOI: 10.2147/OTT.S268309] [Reference Citation Analysis]
14 Kumar V, Mundra V, Peng Y, Wang Y, Tan C, Mahato RI. Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice. Theranostics 2018;8:4033-49. [PMID: 30128034 DOI: 10.7150/thno.24945] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
15 Gach-Janczak K, Drogosz-Stachowicz J, Długosz-Pokorska A, Jakubowski R, Janecki T, Szymański J, Janecka A. A New Hybrid δ-Lactone Induces Apoptosis and Potentiates Anticancer Activity of Taxol in HL-60 Human Leukemia Cells. Molecules 2020;25:E1479. [PMID: 32218198 DOI: 10.3390/molecules25071479] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Tan KX, Danquah MK, Sidhu A, Ongkudon CM, Lau SY. Towards targeted cancer therapy: Aptamer or oncolytic virus? Eur J Pharm Sci 2017;96:8-19. [PMID: 27593990 DOI: 10.1016/j.ejps.2016.08.061] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
17 Egalite N, Groisman IJ, Godard B. Personalized medicine in oncology: ethical implications for the delivery of healthcare. Per Med 2014;11:659-68. [PMID: 29764052 DOI: 10.2217/pme.14.53] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
18 Au TH, Nguyen BN, Nguyen PH, Pethe S, Giang VT, Thu Ha TV. Vinblastine Loaded On Graphene Quantum Dots And Its Anticancer Applications. J Microencapsul 2022;:1-27. [PMID: 35352611 DOI: 10.1080/02652048.2022.2060361] [Reference Citation Analysis]
19 Zheng H, Fridkin M, Youdim M. From single target to multitarget/network therapeutics in Alzheimer's therapy. Pharmaceuticals (Basel) 2014;7:113-35. [PMID: 24463342 DOI: 10.3390/ph7020113] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 9.0] [Reference Citation Analysis]
20 Boye A, Yang Y, Asenso J, Wei W. Anti-fibro-hepatocarcinogenic Chinese herbal medicines: A mechanistic overview. J Intercult Ethnopharmacol 2016;5:278-89. [PMID: 27366355 DOI: 10.5455/jice.20160530032814] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
21 Asik A, Kayabasi C, Ozmen Yelken B, Yılmaz Susluer S, Dogan Sigva ZO, Balcı Okcanoglu T, Saydam G, Biray Avci C, Gunduz C. Antileukemic effect of paclitaxel in combination with metformin in HL-60 cell line. Gene 2018;647:213-20. [DOI: 10.1016/j.gene.2018.01.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
22 Kimura T, Uesugi M, Takase K, Miyamoto N, Sawada K. Hsp90 inhibitor geldanamycin attenuates the cytotoxicity of sunitinib in cardiomyocytes via inhibition of the autophagy pathway. Toxicol Appl Pharmacol 2017;329:282-92. [PMID: 28624441 DOI: 10.1016/j.taap.2017.06.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
23 Fraix A, Manet I, Ballestri M, Guerrini A, Dambruoso P, Sotgiu G, Varchi G, Camerin M, Coppellotti O, Sortino S. Polymer nanoparticles with electrostatically loaded multicargo for combined cancer phototherapy. J Mater Chem B 2015;3:3001-10. [DOI: 10.1039/c5tb00234f] [Cited by in Crossref: 16] [Article Influence: 2.3] [Reference Citation Analysis]
24 Chen TL, Patel AS, Jain V, Kuppusamy R, Lin YW, Hou MH, Su TL, Lee TC. Discovery of Oral Anticancer 1,2-Bis(hydroxymethyl)benzo[g]pyrrolo[2,1-a]phthalazine Hybrids That Inhibit Angiogenesis and Induce DNA Cross-Links. J Med Chem 2021;64:12469-86. [PMID: 34459195 DOI: 10.1021/acs.jmedchem.0c01733] [Reference Citation Analysis]
25 Liu Z, Cao S, Jin C, He Y, Zhou X, Zhang H, Liu Z. The antagonism between apigenin and protoapigenone to the PDK-1 target in Macrothelypteris torresiana. Fitoterapia 2019;134:14-22. [PMID: 30731149 DOI: 10.1016/j.fitote.2019.02.005] [Reference Citation Analysis]
26 Jones VS, Huang R, Chen L, Chen Z, Fu L, Huang R. Cytokines in cancer drug resistance: Cues to new therapeutic strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2016;1865:255-65. [DOI: 10.1016/j.bbcan.2016.03.005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 76] [Article Influence: 7.8] [Reference Citation Analysis]
27 Uitdehaag JC, de Roos JA, van Doornmalen AM, Prinsen MB, Spijkers-Hagelstein JA, de Vetter JR, de Man J, Buijsman RC, Zaman GJ. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. PLoS One 2015;10:e0125021. [PMID: 26018524 DOI: 10.1371/journal.pone.0125021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
28 Lin L, Fang Z, Lin H, You H, Wang J, Su Y, Wang F, Zhang ZY. Depletion of Cks1 and Cks2 expression compromises cell proliferation and enhance chemotherapy-induced apoptosis in HepG2 cells. Oncol Rep 2016;35:26-32. [PMID: 26531156 DOI: 10.3892/or.2015.4372] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
29 Kunjiappan S, Panneerselvam T, Somasundaram B, Sankaranarayanan M, Chowdhury R, Chowdhury A, Bhattacharjee C. Design, in silico modeling, biodistribution study of rutin and quercetin loaded stable human hair keratin nanoparticles intended for anticancer drug delivery. Biomed Phys Eng Express 2018;4:025019. [DOI: 10.1088/2057-1976/aaa1cf] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Tavano L, Muzzalupo R. Multi-functional vesicles for cancer therapy: The ultimate magic bullet. Colloids and Surfaces B: Biointerfaces 2016;147:161-71. [DOI: 10.1016/j.colsurfb.2016.07.060] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 7.7] [Reference Citation Analysis]
31 Saeed M, Jacob S, Sandjo LP, Sugimoto Y, Khalid HE, Opatz T, Thines E, Efferth T. Cytotoxicity of the Sesquiterpene Lactones Neoambrosin and Damsin from Ambrosia maritima Against Multidrug-Resistant Cancer Cells. Front Pharmacol 2015;6:267. [PMID: 26617519 DOI: 10.3389/fphar.2015.00267] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
32 Bashari O, Redko B, Cohen A, Luboshits G, Gellerman G, Firer MA. Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells. Cancer Lett 2017;408:164-73. [PMID: 28888997 DOI: 10.1016/j.canlet.2017.08.040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
33 Goswami U, Kandimalla R, Kalita S, Chattopadhyay A, Ghosh SS. Polyethylene Glycol-Encapsulated Histone Deacetylase Inhibitor Drug-Composite Nanoparticles for Combination Therapy with Artesunate. ACS Omega 2018;3:11504-16. [PMID: 30320264 DOI: 10.1021/acsomega.8b02105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
34 Tinajero-Díaz E, Salado-Leza D, Gonzalez C, Martínez Velázquez M, López Z, Bravo-Madrigal J, Knauth P, Flores-Hernández FY, Herrera-Rodríguez SE, Navarro RE, Cabrera-Wrooman A, Krötzsch E, Carvajal ZYG, Hernández-Gutiérrez R. Green Metallic Nanoparticles for Cancer Therapy: Evaluation Models and Cancer Applications. Pharmaceutics 2021;13:1719. [PMID: 34684012 DOI: 10.3390/pharmaceutics13101719] [Reference Citation Analysis]
35 Albayrak D, Doğanlar O, Erdoğan S, Meraklı M, Doğan A, Turker P, Bostancı A, Doğanlar ZB. Naringin Combined with NF-κB Inhibition and Endoplasmic Reticulum Stress Induces Apoptotic Cell Death via Oxidative Stress and the PERK/eIF2α/ATF4/CHOP Axis in HT29 Colon Cancer Cells. Biochem Genet 2021;59:159-84. [PMID: 32979141 DOI: 10.1007/s10528-020-09996-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
36 de Braud F, Cascinu S, Spitaleri G, Pilz K, Clementi L, Liu D, Sikken P, De Pas T. A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. Annals of Oncology 2015;26:2341-6. [DOI: 10.1093/annonc/mdv354] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
37 Zhang XF, Yan Q, Shen W, Gurunathan S. Trichostatin A Enhances the Apoptotic Potential of Palladium Nanoparticles in Human Cervical Cancer Cells. Int J Mol Sci 2016;17:E1354. [PMID: 27548148 DOI: 10.3390/ijms17081354] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
38 Peixoto-da-silva J, Calgarotto AK, Rocha KR, Palmeira-dos-santos C, Smaili SS, Pereira GJ, Pericole FV, da Silva S. Duarte A, Saad ST, Bincoletto C. Lithium, a classic drug in psychiatry, improves nilotinib-mediated antileukemic effects. Biomedicine & Pharmacotherapy 2018;99:237-44. [DOI: 10.1016/j.biopha.2018.01.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Kline AE, Leary JB, Radabaugh HL, Cheng JP, Bondi CO. Combination therapies for neurobehavioral and cognitive recovery after experimental traumatic brain injury: Is more better? Prog Neurobiol 2016;142:45-67. [PMID: 27166858 DOI: 10.1016/j.pneurobio.2016.05.002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 8.7] [Reference Citation Analysis]
40 Joseph TP, Chanda W, Padhiar AA, Batool S, LiQun S, Zhong M, Huang M. A Preclinical Evaluation of the Antitumor Activities of Edible and Medicinal Mushrooms: A Molecular Insight. Integr Cancer Ther 2018;17:200-9. [PMID: 29094602 DOI: 10.1177/1534735417736861] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
41 Assoun S, Lemiale V, Azoulay E. Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. Intensive Care Med 2019;45:988-97. [PMID: 31143997 DOI: 10.1007/s00134-019-05650-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
42 Ramos P, Bentires-Alj M. Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene. 2014;Epub ahead of print. [PMID: 25263438 DOI: 10.1038/onc.2014.314] [Cited by in Crossref: 138] [Cited by in F6Publishing: 128] [Article Influence: 17.3] [Reference Citation Analysis]
43 Klippstein R, Bansal SS, Al-jamal KT. Doxorubicin enhances curcumin’s cytotoxicity in human prostate cancer cells in vitro by enhancing its cellular uptake. International Journal of Pharmaceutics 2016;514:169-75. [DOI: 10.1016/j.ijpharm.2016.08.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
44 Chawsheen MA, Dash PR. mTOR modulates resistance to gemcitabine in lung cancer in an MTORC2 dependent mechanism. Cell Signal 2021;81:109934. [PMID: 33545231 DOI: 10.1016/j.cellsig.2021.109934] [Reference Citation Analysis]
45 Byun S, Lim S, Mun JY, Kim KH, Ramadhar TR, Farrand L, Shin SH, Thimmegowda NR, Lee HJ, Frank DA, Clardy J, Lee SW, Lee KW. Identification of a Dual Inhibitor of Janus Kinase 2 (JAK2) and p70 Ribosomal S6 Kinase1 (S6K1) Pathways. J Biol Chem 2015;290:23553-62. [PMID: 26242912 DOI: 10.1074/jbc.M115.662445] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
46 Yeang CH, Beckman RA. Long range personalized cancer treatment strategies incorporating evolutionary dynamics. Biol Direct 2016;11:56. [PMID: 27770811 DOI: 10.1186/s13062-016-0153-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
47 Wang J. Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles. Drug Des Devel Ther 2020;14:823-32. [PMID: 32161442 DOI: 10.2147/DDDT.S235098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
48 Yamaguchi R, Perkins G. Deconstructing Signaling Pathways in Cancer for Optimizing Cancer Combination Therapies. IJMS 2017;18:1258. [DOI: 10.3390/ijms18061258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
49 Yokomichi H, Inozume T, Wada M, Asai J, Igaki H, Namikawa K, Hayashi A, Fukushima S, Fujimura T, Koga H, Nakamura Y, Mochizuki M, Yamagata Z. Concordance and Discordance Rates of V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)V600E Status in Metastatic against Primary Lesion of Melanoma: A Meta-analysis. JMA J 2020;3:274-9. [PMID: 33150263 DOI: 10.31662/jmaj.2020-0016] [Reference Citation Analysis]
50 McCabe B, Liberante F, Mills KI. Repurposing medicinal compounds for blood cancer treatment. Ann Hematol 2015;94:1267-76. [PMID: 26048243 DOI: 10.1007/s00277-015-2412-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
51 Twarog NR, Martinez NE, Gartrell J, Xie J, Tinkle CL, Shelat AA. Using response surface models to analyze drug combinations. Drug Discov Today 2021;26:2014-24. [PMID: 34119666 DOI: 10.1016/j.drudis.2021.06.002] [Reference Citation Analysis]
52 Huynh DL, Sharma N, Kumar Singh A, Singh Sodhi S, Zhang JJ, Mongre RK, Ghosh M, Kim N, Ho Park Y, Kee Jeong D. Anti-tumor activity of wogonin, an extract from Scutellaria baicalensis, through regulating different signaling pathways. Chin J Nat Med 2017;15:15-40. [PMID: 28259249 DOI: 10.1016/S1875-5364(17)30005-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
53 Tan KT, Li S, Li YR, Cheng SL, Lin SH, Tung YT. Synergistic Anticancer Effect of a Combination of Paclitaxel and 5-Demethylnobiletin Against Lung Cancer Cell Line In Vitro and In Vivo. Appl Biochem Biotechnol 2019;187:1328-43. [PMID: 30229430 DOI: 10.1007/s12010-018-2869-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
54 Omar HA, Tolba MF, Hung JH, Al-Tel TH. OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53. Front Pharmacol 2016;7:463. [PMID: 27965580 DOI: 10.3389/fphar.2016.00463] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
55 Wang L, You X, Lou Q, He S, Zhang J, Dai C, Zhao M, Zhao M, Hu H, Wu J. Cysteine-based redox-responsive nanoparticles for small-molecule agent delivery. Biomater Sci 2019;7:4218-29. [PMID: 31389415 DOI: 10.1039/c9bm00907h] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 4.3] [Reference Citation Analysis]
56 Kotcherlakota R, Srinivasan DJ, Mukherjee S, Haroon MM, Dar GH, Venkatraman U, Patra CR, Gopal V. Engineered fusion protein-loaded gold nanocarriers for targeted co-delivery of doxorubicin and erbB2-siRNA in human epidermal growth factor receptor-2+ ovarian cancer. J Mater Chem B 2017;5:7082-98. [DOI: 10.1039/c7tb01587a] [Cited by in Crossref: 25] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
57 Ande A, Vaidya TR, Tran BN, Vicchiarelli M, Brown AN, Ait-Oudhia S. Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer. Front Pharmacol 2018;9:403. [PMID: 29765318 DOI: 10.3389/fphar.2018.00403] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
58 Peng XC, Chen XX, Zhang YU, Wang HJ, Feng Y. A novel inhibitor of Rho GDP-dissociation inhibitor α improves the therapeutic efficacy of paclitaxel in Lewis lung carcinoma. Biomed Rep 2015;3:473-7. [PMID: 26171151 DOI: 10.3892/br.2015.475] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
59 Jeevanandam J, Tan KX, Danquah MK, Guo H, Turgeson A. Advancing Aptamers as Molecular Probes for Cancer Theranostic Applications-The Role of Molecular Dynamics Simulation. Biotechnol J 2020;15:e1900368. [PMID: 31840436 DOI: 10.1002/biot.201900368] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
60 Bulusu KC, Guha R, Mason DJ, Lewis RP, Muratov E, Kalantar Motamedi Y, Cokol M, Bender A. Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. Drug Discov Today 2016;21:225-38. [PMID: 26360051 DOI: 10.1016/j.drudis.2015.09.003] [Cited by in Crossref: 97] [Cited by in F6Publishing: 77] [Article Influence: 13.9] [Reference Citation Analysis]
61 Bozeman EN, He S, Shafizadeh Y, Selvaraj P. Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12. Hum Vaccin Immunother 2016;12:421-30. [PMID: 26308597 DOI: 10.1080/21645515.2015.1076953] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
62 Chitkara D, Singh S, Mittal A. Nanocarrier-based co-delivery of small molecules and siRNA/miRNA for treatment of cancer. Ther Deliv 2016;7:245-55. [PMID: 27010986 DOI: 10.4155/tde-2015-0003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
63 Yan D, Wages NA, Dressler EV. Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design. Journal of Biopharmaceutical Statistics 2019;29:333-47. [DOI: 10.1080/10543406.2018.1535496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
64 Yuan YG, Gurunathan S. Combination of graphene oxide-silver nanoparticle nanocomposites and cisplatin enhances apoptosis and autophagy in human cervical cancer cells. Int J Nanomedicine 2017;12:6537-58. [PMID: 28919753 DOI: 10.2147/IJN.S125281] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 8.8] [Reference Citation Analysis]
65 Figueiredo SA, Salvador JA, Cortés R, Cascante M. Novel celastrol derivatives with improved selectivity and enhanced antitumour activity: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry 2017;138:422-37. [DOI: 10.1016/j.ejmech.2017.06.029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
66 Kotani N, Yamaguchi A, Ohnishi T, Kuwahara R, Nakano T, Nakano Y, Ida Y, Murakoshi T, Honke K. Proximity proteomics identifies cancer cell membrane cis-molecular complex as a potential cancer target. Cancer Sci 2019;110:2607-19. [PMID: 31228215 DOI: 10.1111/cas.14108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
67 Westhoff MA, Karpel-Massler G, Brühl O, Enzenmüller S, La Ferla-Brühl K, Siegelin MD, Nonnenmacher L, Debatin KM. A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy. Mol Cell Ther 2014;2:32. [PMID: 26056598 DOI: 10.1186/2052-8426-2-32] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
68 Gach K, Szymański J, Pomorska D, Długosz A, Modranka J, Michalak M, Janecki T, Janecka A. Anticancer properties of novel 4-methylene-1,2-diphenylpyrazolidin-3-ones. Chem Biol Drug Des 2015;86:961-8. [PMID: 25832885 DOI: 10.1111/cbdd.12565] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
69 Ballazhi L, Imeri F, Dimovski A, Jashari A, Popovski E, Breznica-selmani P, Mikhova B, Dräger G, Alili-idrizi E, Mladenovska K. Synergy of novel coumarin derivatives and tamoxifen in blocking growth and inducing apoptosis of breast cancer cells. Maced Pharm Bull 2014;60:35-44. [DOI: 10.33320/maced.pharm.bull.2014.60.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
70 Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP, Vikas P. The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience 2014;8:442. [PMID: 25075216 DOI: 10.3332/ecancer.2014.442] [Cited by in Crossref: 15] [Cited by in F6Publishing: 76] [Article Influence: 1.9] [Reference Citation Analysis]
71 Guo B, Li Y. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering. Stat Med 2015;34:859-75. [PMID: 25413162 DOI: 10.1002/sim.6376] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
72 Baccelli I, Krosl J, Boucher G, Boivin I, Lavallée VP, Hébert J, Lemieux S, Marinier A, Sauvageau G. A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens. Blood Cancer J 2017;7:e529. [PMID: 28211886 DOI: 10.1038/bcj.2017.10] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
73 Tang W, Liu ZL, Mai XY, Qi X, Li DH, Gu QQ, Li J. Identification of Gliotoxin isolated from marine fungus as a new pyruvate kinase M2 inhibitor. Biochem Biophys Res Commun 2020;528:594-600. [PMID: 32507600 DOI: 10.1016/j.bbrc.2020.05.139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
74 Sarisozen C, Pan J, Dutta I, Torchilin VP. Polymers in the co-delivery of siRNA and anticancer drugs to treat multidrug-resistant tumors. Journal of Pharmaceutical Investigation 2017;47:37-49. [DOI: 10.1007/s40005-016-0296-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
75 Bodenstine TM, Chandler GS, Seftor RE, Seftor EA, Hendrix MJ. Plasticity underlies tumor progression: role of Nodal signaling. Cancer Metastasis Rev 2016;35:21-39. [PMID: 26951550 DOI: 10.1007/s10555-016-9605-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
76 Lüpfert C, Dyroff M, von Richter O, Gallemann D, El Bawab S, Dolgos H, Jung D, Hecht S, Johne A. A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide. CPT Pharmacometrics Syst Pharmacol 2018;7:829-37. [PMID: 30311747 DOI: 10.1002/psp4.12360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
77 Sidhu H, Capalash N. Synergistic anti-cancer action of salicylic acid and cisplatin on HeLa cells elucidated by network pharmacology and in vitro analysis. Life Sci 2021;282:119802. [PMID: 34237314 DOI: 10.1016/j.lfs.2021.119802] [Reference Citation Analysis]
78 Kulkarni MR, Mane MS, Ghosh U, Sharma R, Lad NP, Srivastava A, Kulkarni-Almeida A, Kharkar PS, Khedkar VM, Pandit SS. Discovery of tetrahydrocarbazoles as dual pERK and pRb inhibitors. Eur J Med Chem 2017;134:366-78. [PMID: 28431342 DOI: 10.1016/j.ejmech.2017.02.062] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
79 Nishisaka F, Taniguchi K, Tsugane M, Hirata G, Takagi A, Asakawa N, Kurita A, Takahashi H, Ogo N, Shishido Y, Asai A. Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701. Cancer Sci 2020;111:1774-84. [PMID: 32112605 DOI: 10.1111/cas.14369] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]